News | Cardiovascular Clinical Studies | August 12, 2022

Johns Hopkins Researchers Find Link Between Dementia and Atrial Cardiopathy

Older adults with atrial cardiopathy (a major, often undetected cardiac cause of stroke) may be at increased risk of developing dementia, according to new research led by Johns Hopkins Medicine.

August 12, 2022 —  Older adults with atrial cardiopathy (a major, often undetected cardiac cause of stroke) may be at increased risk of developing dementia, according to new research led by Johns Hopkins Medicine

The findings were published Aug. 10 in the Journal of the American Heart Association

More than 55 million people live with dementia worldwide, and there are nearly 10 million new cases every year, according to the World Health Organization. Dementia is the loss of cognitive functioning — thinking, remembering and reasoning — to such an extent that it interferes with a person’s daily life and activities. 

Johns Hopkins Medicine researchers studied 5,078 older adults living in four U.S. communities: Washington County, Maryland; Forsyth County, North Carolina; northwestern suburbs of Minneapolis; and Jackson, Mississippi. The participants did not have dementia when the study began. The researchers sought to determine if there was a difference in the number of people who developed dementia by comparing a group that had markers of left atrial (one chamber of the heart) dysfunction versus those who did not. 

Stroke and atrial fibrillation are two medical conditions tied to atrial cardiopathy [dysfunction of the atrium, or left upper cavity of the heart],” says study author Michelle Johansen, M.D., Ph.D., an assistant professor of neurology at the Johns Hopkins University School of Medicine and an attending physician in The Johns Hopkins Hospital’s cerebrovascular division. “We looked to see if we could find any association between the left atrium and dementia that was mediated by, or as a result of, the development of either one of these conditions.” 

In the study, Johansen and her colleagues found that the prevalence of atrial cardiopathy among participants was 34%. The mean age of the participants was 75, and 59% were female adults and 21% were Black adults.

Johansen says the team looked at three markers that could be obtained from routine medical tests to measure the function of the left atrium. These include an echocardiogram (a test of the heart action using ultrasound waves to produce a visual display), an electrocardiogram (a record or display of a person’s heartbeat) and a blood marker that determines how the heart functions. Using these three tests, the team established a definition of atrial cardiopathy and then grouped participants into whether they met this definition.

"We found that patients who had atrial cardiopathy as we defined in our study had a higher hazard, or rate, of dementia over time versus those who did not have atrial cardiopathy,” Johansen says.

She also says this is believed to be the first time this has been shown to be the case. Additionally, the team found that the effect was not mediated through either atrial fibrillation or stroke despite that these medical conditions are known to be associated with dementia

Johansen says the study is important for people without symptomatic cardiac disease. Those with rather subtle changes in the left atrium are at an increased risk of dementia even after controlling for other vascular risk factors. In future research, the team hopes to understand the mechanism behind this association better. 

For more information: https://www.hopkinsmedicine.org/


Related Content

News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
News | Cardiovascular Clinical Studies

Jan. 13, — A new cohort study among 103,642 adults found that current use of cigars was associated with increased risk ...

Home January 14, 2025
Home
News | Cardiovascular Clinical Studies

Nov. 22, 2024 — BridgeBio Pharma, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved ...

Home November 25, 2024
Home
News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
Subscribe Now